Lord, Abbett & Co
HAE icon

Lord, Abbett & Co’s Haemonetics HAE Stock Holding History

Lord, Abbett & Co’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-76,862
Closed -$6.72M – 787
2019
Q1 		$6.72M Sell
76,862
-126,296
-62% -$11.5M 0.02% 622
2018
Q4 		$20.3M Buy
+203,158
New +$21.3M 0.07% 386
2013
Q4 		– Sell
-129,928
Closed -$5.18M – 1064
2013
Q3 		$5.18M Sell
129,928
-789,772
-86% -$33.1M 0.01% 789
2013
Q2 		$38M Buy
+919,700
New +$37.2M 0.09% 347

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Lord, Abbett & Co's HAE Position: Q2 2019 in Review

Lord, Abbett & Co sold out of Haemonetics (HAE) in Q2 2019, closing a stake of 76,862 shares — an estimated $6.72M sold.

Lord, Abbett & Co first reported a position in HAE in Q2 2013 and held it in 4 quarters. The position peaked at $38M in Q2 2013. 256 funds tracked by Wall St. Rank hold HAE as of Q2 2019.

  • Lord, Abbett & Co reported no remaining Haemonetics position as of Q2 2019 after selling out during the quarter.
  • Lord, Abbett & Co sold 76,862 Haemonetics shares in Q2 2019, an estimated $6.72M.
  • Lord, Abbett & Co first reported a position in Haemonetics in Q2 2013 and held it in 4 quarters.
  • Lord, Abbett & Co's Haemonetics position peaked at $38M in Q2 2013.
  • 256 funds tracked by Wall St. Rank held Haemonetics as of Q2 2019.

Based on Lord, Abbett & Co's 13F filing for Q2 2019, filed 14 Aug 2019.